Haiyan Chen

Haiyan Chen

Auto-generated profile, based on publicly available information

Haiyan Chen

Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 October 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
AWAshley Woods
Ashley Woods
KNKelly J. Norsworthy
Kelly J. Norsworthy
MCMoran Choe
Moran Choe
BGBrenda J. Gehrke
Brenda J. Gehrke
HCHaiyan Chen
Haiyan Chen
RCR. Angelo de Claro
R. Angelo de Claro
On December 1, 2022, the FDA approved the new molecular entity olutasidenib (Rezlidhia, Rigel Pharmaceuticals), a small-molecule inhibitor of isocitrate dehydrogenase 1, for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with a susceptible isocitrate dehydrogenase 1 mutation as detected by an FDA-approved test. The efficacy of olutasidenib was established based on complete remission (CR) + CR with partial hematologic recovery (CRh) rate, duration of CR + CRh, and conversion of transfusion dependence to transfusion independence in Study 2102-HEM-101. In the pivotal trial, 147 adult patients treated with 150 mg twice daily of olutasidenib were evaluable for efficacy. With a median follow-up of 10.2 months, the CR/CRh rate was 35% (95% confidence interval, 27%–43%), with a median duration of response of 25.9 months [95% confidence interval, 13.5–not reached]. Of the 86 patients who were transfusion dependent at baseline, 29 became transfusion independent (34%). The most common (≥20%) adverse reactions were nausea, fatigue, arthralgia, leukocytosis, dyspnea, pyrexia, rash, mucositis, diarrhea, and transaminitis. An assessment of long-term safety of olutasidenib is a condition of this approval.

1 August 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
GPGulsum Emel Pamuk
Gulsum Emel Pamuk
ECEdwin C.Y. Chow
Edwin C.Y. Chow
AIAlexei C. Ionan
Alexei C. Ionan
HCHaiyan Chen
Haiyan Chen
SLShwu-Luan Lee
Shwu-Luan Lee
MTMarc R. Theoret
Marc R. Theoret
On October 29, 2021, FDA granted accelerated approval to asciminib (SCEMBLIX; Novartis), a tyrosine kinase inhibitor (TKI), for the treatment of adult patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), previously treated with two or more TKIs, and granted traditional approval to asciminib for adult patients with Ph+ CML in CP with the T315I mutation. The first indication was approved based on major molecular response (MMR) at 24 weeks in the ASCEMBL study, a randomized trial comparing asciminib with bosutinib in patients who had failed two or more TKIs. This indication was ultimately granted traditional approval on October 12, 2022, based on safety data and MMR rate at 96 weeks of 38% [95% confidence interval (CI), 30–46] in the asciminib arm versus 16% (95% CI, 8–26) in the bosutinib arm (P value: 0.001). The second indication was approved based on MMR rate by 96 weeks of 49% (95% CI, 34–64) in the single-arm CABL001X2101 study. The most common (≥20%) adverse reactions included upper respiratory tract infections, musculoskeletal pain, headache, fatigue, nausea, rash, and diarrhea. The most common (≥20%) laboratory abnormalities were thrombocytopenia, neutropenia, anemia, lymphopenia, hypertriglyceridemia, hyperuricemia, and increases in creatine kinase, alanine aminotransferase, aspartate aminotransferase, lipase, and amylase. This manuscript describes the basis for approval of these indications.

17 June 2026
Verified
Other
Open access
AWAshley Woods
Ashley Woods
KNKelly J. Norsworthy
Kelly J. Norsworthy
MCMoran Choe
Moran Choe
BGBrenda J. Gehrke
Brenda J. Gehrke
HCHaiyan Chen
Haiyan Chen
RCR. Angelo de Claro
R. Angelo de Claro
On December 1, 2022, the FDA approved the new molecular entity olutasidenib (Rezlidhia, Rigel Pharmaceuticals), a small-molecule inhibitor of isocitrate dehydrogenase 1, for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with a susceptible isocitrate dehydrogenase 1 mutation as detected by an FDA-approved test. The efficacy of olutasidenib was established based on complete remission (CR) + CR with partial hematologic recovery (CRh) rate, duration of CR + CRh, and conversion of transfusion dependence to transfusion independence in Study 2102-HEM-101. In the pivotal trial, 147 adult patients treated with 150 mg twice daily of olutasidenib were evaluable for efficacy. With a median follow-up of 10.2 months, the CR/CRh rate was 35% (95% confidence interval, 27%–43%), with a median duration of response of 25.9 months [95% confidence interval, 13.5–not reached]. Of the 86 patients who were transfusion dependent at baseline, 29 became transfusion independent (34%). The most common (≥20%) adverse reactions were nausea, fatigue, arthralgia, leukocytosis, dyspnea, pyrexia, rash, mucositis, diarrhea, and transaminitis. An assessment of long-term safety of olutasidenib is a condition of this approval.

17 June 2026
Verified
Other
Open access
GPGulsum Emel Pamuk
Gulsum Emel Pamuk
ECEdwin C.Y. Chow
Edwin C.Y. Chow
AIAlexei C. Ionan
Alexei C. Ionan
HCHaiyan Chen
Haiyan Chen
SLShwu-Luan Lee
Shwu-Luan Lee
MTMarc R. Theoret
Marc R. Theoret
Select laboratory abnormalities (≥ 10%) that worsened from baseline in patients with Ph + CML in CP with the T315I mutation in X2101 trial


17 June 2026
Verified
Other
Open access
PDF file
GPGulsum Emel Pamuk
Gulsum Emel Pamuk
ECEdwin C.Y. Chow
Edwin C.Y. Chow
AIAlexei C. Ionan
Alexei C. Ionan
HCHaiyan Chen
Haiyan Chen
SLShwu-Luan Lee
Shwu-Luan Lee
MTMarc R. Theoret
Marc R. Theoret
The list of preferred terms included in grouped terms used for safety analysis in ASCEMBL